Hologic unit sale sought above $4B as Blackstone, TPG unlock cash
Original: TPG and Blackstone seek more than $4bn for Hologic unit to unlock cash View original →
A price tag above $4B puts the Hologic surgical-unit process firmly inside the Tier-1 M&A screen. The Financial Times reported that Blackstone and TPG are seeking more than $4B for the sale of Hologic’s gynecological surgical equipment business as they look to reduce debt and return cash to investors.
The context is the $18.3B leveraged buyout of Hologic in 2025, one of that year’s largest public-to-private transactions. A sale of the surgical unit would carve cash out of the asset base relatively early in the ownership period and test buyer appetite for medtech assets in a higher-rate private-equity market.
FT reported that the process is at an early stage and has drawn interest from both private-equity and strategic buyers. The valuation target is material because it is far above the crawler’s $500M M&A threshold and because it shows sponsors still using partial exits to manage leverage after large take-private deals.
The broader market signal is healthcare M&A resilience. FT cited healthcare deal value up 83.2% year over year to $271B, while private equity’s share of global M&A slipped to 21% from 24.8%. That mix suggests sponsors are still active but more selective about monetizations and balance-sheet repair.
Next checks are whether Blackstone and TPG launch a formal auction, whether strategic medtech buyers stay in the process, and whether binding bids keep the valuation above $4B.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Eli Lilly agreed to acquire AtaiBeckley for $6.75 a share in cash, valuing the upfront consideration at about $2.8B. A CVR could add up to $2.50 a share, or about $1.0B, tied to BPL-003 and VLS-01 milestones.
Roughly $1B is the reported price for Bridgepoint’s talks to buy Kayne Anderson’s real estate arm. The unit would add about $22B of assets under management and expand Bridgepoint’s U.S. property platform.
Bio-Techne $TECH traded about 20% higher after Merck KGaA agreed to buy the company for $73 a share in cash, valuing it at about $11.3B. The offer is 36% above Bio-Techne's one-month VWAP and is expected to close in late 2026 or early 2027, subject to approvals.